Dr. Christoph Correll has expertise in the diagnosis and management of severe mental disorders in youths and adults. His areas of research include the identification and treatment of mood disorders, schizophrenia and the psychotic and bipolar prodrome as well as the assessment of psychotropic medications at all illness stages, utilizing a wide range of clinical and basic science methods, including clinical trials in psychopharmacology, pharmacogenetics, and molecular biology. Within this framework, his work further focuses on the utilization and risk-benefit evaluation of psychopharmacologic treatments, particularly second-generation antipsychotic drugs.
Because of his expertise in antipsychotic-related side effects, Dr. Correll was an observing member of the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, and has served as a member of the American Psychiatric Association Work Group on Diabetes and Second-Generation Antipsychotic Agents. In addition, Dr. Correll is a diplomate in both psychiatry and child and adolescent psychiatry for the American Board of Neurology and Psychiatry.
Dr. Correll has been interviewed and listed in several media outlets about psychiatric issues and is the recipient of more than 20 research awards and fellowships. He is the author of scientific literature on the identification and early intervention of individuals at high risk for schizophrenia and bipolar disorder, as well as on the risks assessment of antipsychotic medications. He is also a reviewer for many scientific journals.
You need to be logged in to save this episode to a playlist.